Phase I and pharmacokinetic study of a low-clearance, unilamellar liposomal formulation of lurtotecan, a topoisomerase 1 inhibitor, in patients with advanced leukemia.

Download in:

• JSON
• RDF
• N3/Turtle
• N-Triples

View as

• Triples